Prothena Corporation plc (PRTA)
USD 10.89
(-3.8%)
USD 10.89
(-3.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 696.38 Million USD | -8.13% |
| 2022 | 758.03 Million USD | 24.4% |
| 2021 | 609.36 Million USD | 83.01% |
| 2020 | 332.97 Million USD | -20.58% |
| 2019 | 419.26 Million USD | -15.94% |
| 2018 | 498.79 Million USD | 0.5% |
| 2017 | 496.32 Million USD | 7.9% |
| 2016 | 459.97 Million USD | 19.4% |
| 2015 | 385.23 Million USD | 26.67% |
| 2014 | 304.11 Million USD | 66.72% |
| 2013 | 182.41 Million USD | 41.09% |
| 2012 | 129.28 Million USD | 3473.33% |
| 2011 | 3.61 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 645.56 Million USD | 3.59% |
| 2024 Q1 | 623.19 Million USD | -10.51% |
| 2023 Q4 | 696.38 Million USD | -6.77% |
| 2023 FY | 696.38 Million USD | -8.13% |
| 2023 Q2 | 720.64 Million USD | -2.82% |
| 2023 Q1 | 741.58 Million USD | -2.17% |
| 2023 Q3 | 746.92 Million USD | 3.65% |
| 2022 Q4 | 758.03 Million USD | 36.72% |
| 2022 Q1 | 581.41 Million USD | -4.59% |
| 2022 FY | 758.03 Million USD | 24.4% |
| 2022 Q3 | 554.44 Million USD | 0.88% |
| 2022 Q2 | 549.58 Million USD | -5.47% |
| 2021 Q3 | 632.7 Million USD | 44.99% |
| 2021 Q2 | 436.37 Million USD | 14.92% |
| 2021 Q4 | 609.36 Million USD | -3.69% |
| 2021 Q1 | 379.71 Million USD | 14.04% |
| 2021 FY | 609.36 Million USD | 83.01% |
| 2020 Q3 | 355.78 Million USD | -6.11% |
| 2020 FY | 332.97 Million USD | -20.58% |
| 2020 Q2 | 378.93 Million USD | -5.13% |
| 2020 Q1 | 399.42 Million USD | -4.73% |
| 2020 Q4 | 332.97 Million USD | -6.41% |
| 2019 Q2 | 462.07 Million USD | 0.55% |
| 2019 Q4 | 419.26 Million USD | -7.01% |
| 2019 FY | 419.26 Million USD | -15.94% |
| 2019 Q3 | 450.89 Million USD | -2.42% |
| 2019 Q1 | 459.53 Million USD | -7.87% |
| 2018 Q1 | 606.64 Million USD | 22.23% |
| 2018 FY | 498.79 Million USD | 0.5% |
| 2018 Q4 | 498.79 Million USD | -4.92% |
| 2018 Q3 | 524.62 Million USD | -6.87% |
| 2018 Q2 | 563.3 Million USD | -7.15% |
| 2017 FY | 496.32 Million USD | 7.9% |
| 2017 Q1 | 581.95 Million USD | 26.52% |
| 2017 Q2 | 579 Million USD | -0.51% |
| 2017 Q3 | 537.68 Million USD | -7.14% |
| 2017 Q4 | 496.32 Million USD | -7.69% |
| 2016 Q1 | 491.3 Million USD | 27.53% |
| 2016 FY | 459.97 Million USD | 19.4% |
| 2016 Q2 | 502.56 Million USD | 2.29% |
| 2016 Q4 | 459.97 Million USD | -4.09% |
| 2016 Q3 | 479.58 Million USD | -4.57% |
| 2015 Q1 | 289.58 Million USD | -4.78% |
| 2015 Q4 | 385.23 Million USD | -3.43% |
| 2015 FY | 385.23 Million USD | 26.67% |
| 2015 Q3 | 398.93 Million USD | -2.98% |
| 2015 Q2 | 411.16 Million USD | 41.98% |
| 2014 Q1 | 203.81 Million USD | 11.73% |
| 2014 Q4 | 304.11 Million USD | -3.02% |
| 2014 Q3 | 313.59 Million USD | 0.61% |
| 2014 FY | 304.11 Million USD | 66.72% |
| 2014 Q2 | 311.68 Million USD | 52.93% |
| 2013 Q1 | 124.26 Million USD | -3.88% |
| 2013 Q2 | 117.93 Million USD | -5.1% |
| 2013 Q3 | 107.93 Million USD | -8.47% |
| 2013 Q4 | 182.41 Million USD | 69.0% |
| 2013 FY | 182.41 Million USD | 41.09% |
| 2012 Q3 | 3.6 Million USD | 0.0% |
| 2012 Q4 | 129.28 Million USD | 3491.19% |
| 2012 FY | 129.28 Million USD | 3473.33% |
| 2011 FY | 3.61 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 53.203% |
| Alkermes plc | 2.13 Billion USD | 67.401% |
| Agenus Inc. | 313.91 Million USD | -121.839% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 81.817% |
| Aptorum Group Limited | 20.64 Million USD | -3273.929% |
| Ardelyx, Inc. | 297.57 Million USD | -134.016% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 9.035% |
| Bicycle Therapeutics plc | 595.34 Million USD | -16.971% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -844.862% |
| ChromaDex Corporation | 54.96 Million USD | -1166.978% |
| Chimerix, Inc. | 212.77 Million USD | -227.287% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2363.117% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -57.921% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 68.766% |
| Precision BioSciences, Inc. | 159.78 Million USD | -335.835% |
| Dyadic International, Inc. | 8.21 Million USD | -8372.588% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2094.02% |
| Fortress Biotech, Inc. | 167.52 Million USD | -315.686% |
| Lantern Pharma Inc. | 43.64 Million USD | -1495.464% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -331.632% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -4700.434% |
| Incyte Corporation | 6.78 Billion USD | 89.732% |
| IO Biotech, Inc. | 150.71 Million USD | -362.043% |
| Jaguar Health, Inc. | 50.76 Million USD | -1271.83% |
| Novavax, Inc. | 1.85 Billion USD | 62.466% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -83.062% |
| Opthea Limited | 188.79 Million USD | -268.864% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 16.407% |
| ContextLogic Inc. | 423 Million USD | -64.629% |
| MiMedx Group, Inc. | 239.04 Million USD | -191.316% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -300.851% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -13370.45% |
| NextCure, Inc. | 129.41 Million USD | -438.087% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1190.839% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1796.0% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2055.915% |
| Vaxcyte, Inc. | 1.4 Billion USD | 50.538% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1072.556% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -8.717% |
| Pharming Group N.V. | 462.85 Million USD | -50.454% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1700.367% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -10.791% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3579.951% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -3579.951% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -321.233% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1437.708% |
| Acelyrin, Inc. | 742.69 Million USD | 6.235% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -10472.832% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -10775.871% |
| Summit Therapeutics Inc. | 202.94 Million USD | -243.132% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -836.325% |
| Senti Biosciences, Inc. | 119.48 Million USD | -482.824% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -204.973% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -314.084% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -8327.714% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -14487.68% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -48.422% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -463.174% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -153.277% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -47.276% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -6791.46% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -224.645% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -61409.205% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -68.272% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3394.988% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -88.199% |
| MEI Pharma, Inc. | 41.37 Million USD | -1583.098% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2048.929% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -104.339% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -494.056% |
| Fortress Biotech, Inc. | 167.52 Million USD | -315.686% |
| Precigen, Inc. | 151.04 Million USD | -361.049% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1947.099% |
| AlloVir, Inc. | 190.79 Million USD | -264.988% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -84.986% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -37.566% |
| ImmuCell Corporation | 43.8 Million USD | -1489.619% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -7.249% |
| Onconetix, Inc. | 88.82 Million USD | -684.025% |
| PureTech Health plc | 693.97 Million USD | -0.347% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -612.885% |
| Elevation Oncology, Inc. | 89.09 Million USD | -681.652% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -11128.346% |
| Seer, Inc. | 436.26 Million USD | -59.622% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -753.441% |
| Innoviva, Inc. | 1.24 Billion USD | 43.999% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -425.877% |
| ESSA Pharma Inc. | 149.12 Million USD | -366.988% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1436.708% |
| GT Biopharma, Inc. | 14.1 Million USD | -4835.729% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -126.177% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -188.115% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -47.568% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1273.616% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -631.402% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -110158.903% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -22.962% |
| Aptose Biosciences Inc. | 12.92 Million USD | -5288.892% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3049.014% |
| Soligenix, Inc. | 9.79 Million USD | -7007.878% |
| Century Therapeutics, Inc. | 360.69 Million USD | -93.069% |
| Kura Oncology, Inc. | 448.93 Million USD | -55.119% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -155.883% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -3926.493% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -527.873% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -239.449% |
| Autolus Therapeutics plc | 375.38 Million USD | -85.513% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -176.742% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -96.062% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1317.37% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -5.331% |
| GRI Bio, Inc. | 2.95 Million USD | -23458.254% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -6466.404% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -308.399% |
| IGM Biosciences, Inc. | 423.41 Million USD | -64.47% |
| INmune Bio, Inc. | 57 Million USD | -1121.701% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -212.972% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -729.606% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2566.408% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -10017.133% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -825.72% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -372.899% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -320.764% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -10.606% |
| Verastem, Inc. | 149.71 Million USD | -365.129% |
| Abeona Therapeutics Inc. | 64 Million USD | -988.063% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -35.971% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -350.858% |
| Histogen Inc. | 19.07 Million USD | -3551.14% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -2974.511% |
| Surrozen, Inc. | 46.08 Million USD | -1411.246% |
| Organovo Holdings, Inc. | 6.34 Million USD | -10868.373% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -16062.53% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -383.509% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -5800.542% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -825.203% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -8074.217% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -91.857% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -3748.606% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -62.175% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -5421.705% |
| Apollomics, Inc. | 55.38 Million USD | -1157.302% |
| Amarin Corporation plc | 831.68 Million USD | 16.268% |
| Mesoblast Limited | 669.15 Million USD | -4.069% |
| Turnstone Biologics Corp. | 112.81 Million USD | -517.278% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -20.95% |
| Synaptogenix, Inc. | 31.11 Million USD | -2138.187% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -5615.545% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -27.063% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -11758.839% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -9380.829% |
| Exelixis, Inc. | 2.94 Billion USD | 76.333% |
| Better Therapeutics, Inc. | 22.94 Million USD | -2935.27% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -91.031% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 11.708% |
| NLS Pharmaceutics AG | 1.84 Million USD | -37610.741% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -8628.086% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -4638.904% |
| Gritstone bio, Inc. | 177.76 Million USD | -291.734% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -630.113% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -3798.62% |
| Avid Bioservices, Inc. | 336.55 Million USD | -106.914% |
| Insmed Incorporated | 1.32 Billion USD | 47.634% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -7132.624% |
| MediWound Ltd. | 66.45 Million USD | -947.837% |
| OmniAb, Inc. | 401.98 Million USD | -73.236% |
| Alector, Inc. | 621.82 Million USD | -11.99% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -94.195% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -12848.717% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1128.36% |
| Zai Lab Limited | 1.03 Billion USD | 32.801% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -45.548% |
| Aura Biosciences, Inc. | 255.07 Million USD | -173.011% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 7.153% |
| Immunic, Inc. | 54.29 Million USD | -1182.495% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -161.577% |
| Veracyte, Inc. | 1.13 Billion USD | 38.797% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -5790.17% |
| FibroGen, Inc. | 423.52 Million USD | -64.424% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -19723.0% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -14602.134% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -12725.948% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 93.888% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -7808.938% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -34.579% |
| TG Therapeutics, Inc. | 329.58 Million USD | -111.289% |
| Galecto, Inc. | 38.22 Million USD | -1721.702% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2328.449% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 84.018% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -195.824% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -2703.245% |
| XBiotech Inc. | 227.24 Million USD | -206.448% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -630.113% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -388.346% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -143.562% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -444.606% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -82.299% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 53.295% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -90.872% |
| Vaxxinity, Inc. | 44.35 Million USD | -1470.09% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -34.707% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -3642.112% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -128.285% |
| NexImmune, Inc. | 8.59 Million USD | -8003.167% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -6399.017% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -3965.897% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.895% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3043.776% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -177428.457% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -301.769% |
| Ainos, Inc. | 31.84 Million USD | -2087.005% |
| Pluri Inc. | 39.52 Million USD | -1661.788% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -146.406% |
| Celularity Inc. | 143.88 Million USD | -383.972% |
| Rallybio Corporation | 115.62 Million USD | -502.302% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1031.776% |
| MeiraGTx Holdings plc | 458.16 Million USD | -51.993% |
| Omeros Corporation | 378.26 Million USD | -84.097% |
| Humacyte, Inc. | 128.22 Million USD | -443.102% |
| Immunocore Holdings plc | 597 Million USD | -16.647% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2127.781% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -916.171% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 33.63% |
| CalciMedica, Inc. | 12.18 Million USD | -5615.076% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -174.544% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -307.46% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -123.892% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -23.188% |
| Pulmatrix, Inc. | 33.95 Million USD | -1950.716% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2465.321% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -394.386% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 46.472% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -434.901% |
| Cytokinetics, Incorporated | 824.31 Million USD | 15.52% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3196.795% |
| Nutriband Inc. | 7.51 Million USD | -9163.905% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -782.01% |
| Vor Biopharma Inc. | 209.82 Million USD | -231.882% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 90.358% |
| Evogene Ltd. | 51.1 Million USD | -1262.756% |
| ProKidney Corp. | 420.55 Million USD | -65.588% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1170.005% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -7214.723% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -27.454% |
| CorMedix Inc. | 82.05 Million USD | -748.626% |
| BioLineRx Ltd. | 63.92 Million USD | -989.373% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -72.985% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2369.44% |
| Atai Life Sciences N.V. | 293.47 Million USD | -137.286% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -326.889% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -446.533% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -23.905% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -620.005% |
| MediciNova, Inc. | 66.26 Million USD | -950.826% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -691.811% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -15505.671% |
| GeoVax Labs, Inc. | 9.28 Million USD | -7401.514% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -18.385% |
| Biomea Fusion, Inc. | 199.92 Million USD | -248.318% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 63.41% |
| Mereo BioPharma Group plc | 66.49 Million USD | -947.207% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -43.556% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -13.625% |
| Absci Corporation | 234.48 Million USD | -196.99% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -9419.918% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -104.884% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -321.84% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -32.311% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -150.774% |
| Allakos Inc. | 243.61 Million USD | -185.859% |
| Imunon, Inc. | 21.91 Million USD | -3077.205% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -170.236% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -12.046% |
| BioAtla, Inc. | 119.65 Million USD | -481.977% |
| NLS Pharmaceutics AG | 1.84 Million USD | -37610.741% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -21526.77% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -8.329% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -625.889% |
| XOMA Corporation | 234.3 Million USD | -197.217% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -214.77% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -453.369% |
| aTyr Pharma, Inc. | 122.06 Million USD | -470.492% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -352.481% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -20.01% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -41.996% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -530.387% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -4494.289% |
| Akari Therapeutics, Plc | 4.35 Million USD | -15890.402% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3987.389% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 59.823% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -22480.582% |
| UroGen Pharma Ltd. | 178.31 Million USD | -290.543% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -47.935% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -125212.795% |
| Orgenesis Inc. | 14.55 Million USD | -4685.473% |
| Entera Bio Ltd. | 11.76 Million USD | -5819.099% |
| GH Research PLC | 226.3 Million USD | -207.725% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1173.233% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -548.183% |
| Xencor, Inc. | 952.69 Million USD | 26.904% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -8846.589% |
| Replimune Group, Inc. | 487.72 Million USD | -42.783% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -8528.105% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -7.393% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -22480.582% |
| Portage Biotech Inc. | 7.77 Million USD | -8852.076% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -15505.671% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -151.451% |
| OncoCyte Corporation | 74.89 Million USD | -829.848% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -34149.732% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -11934.3% |
| Purple Biotech Ltd. | 44.3 Million USD | -1471.897% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1940.62% |
| scPharmaceuticals Inc. | 94.47 Million USD | -637.076% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -3759.15% |
| HilleVax, Inc. | 344.43 Million USD | -102.182% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -21826.385% |
| Tharimmune, Inc. | 10.94 Million USD | -6261.749% |
| Genprex, Inc. | 10.67 Million USD | -6426.18% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -40.344% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -623.499% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -28604.946% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -16618.086% |
| OKYO Pharma Limited | 1.54 Million USD | -45082.526% |
| Savara Inc. | 177.56 Million USD | -292.186% |
| Curis, Inc. | 77.28 Million USD | -801.092% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3172.131% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -988.968% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -8512.194% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3494.972% |
| BeiGene, Ltd. | 5.8 Billion USD | 88.004% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -5622.59% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 66.658% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -94.547% |
| Erasca, Inc. | 395.29 Million USD | -76.167% |
| bluebird bio, Inc. | 619.16 Million USD | -12.472% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -16007.392% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 89.821% |
| DBV Technologies S.A. | 182.98 Million USD | -280.566% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -16007.392% |
| Moderna, Inc. | 18.42 Billion USD | 96.221% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -3722.704% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -5910.547% |
| Molecular Templates, Inc. | 35.38 Million USD | -1868.126% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -403.657% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 11.729% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -129.258% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -569.946% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -49.558% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -122.176% |
| MacroGenics, Inc. | 306.82 Million USD | -126.968% |
| RenovoRx, Inc. | 1.46 Million USD | -47402.183% |
| Adicet Bio, Inc. | 207.29 Million USD | -235.938% |
| Prime Medicine, Inc. | 193.85 Million USD | -259.236% |
| Aditxt, Inc. | 44.57 Million USD | -1462.154% |
| Adagene Inc. | 115.72 Million USD | -501.736% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -15534.316% |
| Quantum-Si incorporated | 298.25 Million USD | -133.489% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 53.183% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -8933.219% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -98.241% |
| SciSparc Ltd. | 11.18 Million USD | -6127.705% |
| Vericel Corporation | 353.65 Million USD | -96.909% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5602.156% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1123.857% |
| Generation Bio Co. | 374.75 Million USD | -85.822% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -173.449% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -339.172% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -103.999% |
| Invivyd, Inc. | 229.18 Million USD | -203.857% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 17.488% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -5622.449% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -281.809% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3309.626% |
| 2seventy bio, Inc. | 565.42 Million USD | -23.161% |
| ADMA Biologics, Inc. | 329.18 Million USD | -111.549% |
| Clene Inc. | 52.34 Million USD | -1230.471% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1085.647% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -436.116% |
| GeoVax Labs, Inc. | 9.28 Million USD | -7401.514% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -6.529% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -572.111% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -434.093% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -613.857% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -880.861% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -187.105% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 64.472% |
| Evaxion Biotech A/S | 12.88 Million USD | -5303.077% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -176.276% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 7.481% |
| Trevena, Inc. | 40.6 Million USD | -1615.015% |
| Surrozen, Inc. | 46.08 Million USD | -1411.246% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -208.329% |
| Cingulate Inc. | 3.49 Million USD | -19845.432% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4087.756% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -960.104% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -5859.814% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -159.344% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 7.02% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -453.158% |
| Clearmind Medicine Inc. | 4.32 Million USD | -16003.593% |
| Kronos Bio, Inc. | 213.27 Million USD | -226.512% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -335.827% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8034.724% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -88.983% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3189.525% |
| ImmunityBio, Inc. | 504.45 Million USD | -38.047% |
| Korro Bio, Inc. | 221.66 Million USD | -214.162% |
| Kineta, Inc. | 10.28 Million USD | -6673.485% |
| BioVie Inc. | 25.2 Million USD | -2662.506% |
| Codexis, Inc. | 136.56 Million USD | -409.942% |
| Celularity Inc. | 143.88 Million USD | -383.972% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -9.606% |
| Celcuity Inc. | 191.21 Million USD | -264.18% |
| Virax Biolabs Group Limited | 5.48 Million USD | -12598.504% |
| Cibus, Inc. | 544.41 Million USD | -27.915% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -453.149% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3289.71% |
| IN8bio, Inc. | 33.7 Million USD | -1965.864% |
| Kodiak Sciences Inc. | 479.37 Million USD | -45.27% |
| Annexon, Inc. | 297.67 Million USD | -133.941% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -302.51% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -406.574% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3217.21% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 76.71% |
| Eyenovia, Inc. | 28.77 Million USD | -2319.726% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -202.081% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -9539.839% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1042.996% |
| Arcellx, Inc. | 825.13 Million USD | 15.604% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -753.023% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -50.642% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2164.657% |
| Moolec Science SA | 24.05 Million USD | -2795.404% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -124.549% |
| Geron Corporation | 394.07 Million USD | -76.713% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -584.674% |
| Royalty Pharma plc | 16.38 Billion USD | 95.749% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -17.045% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -9855.689% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -5690.003% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -208.052% |
| Humacyte, Inc. | 128.22 Million USD | -443.102% |
| Structure Therapeutics Inc. | 482.01 Million USD | -44.472% |
| 89bio, Inc. | 596.26 Million USD | -16.79% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -176.175% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -37542.27% |
| Genelux Corporation | 27.89 Million USD | -2396.619% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -678.925% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -203.528% |
| Notable Labs, Ltd. | 19.54 Million USD | -3463.697% |
| Liquidia Corporation | 120.43 Million USD | -478.241% |
| Mustang Bio, Inc. | 17.74 Million USD | -3825.048% |
| Immunovant, Inc. | 666.71 Million USD | -4.45% |
| Quantum-Si incorporated | 298.25 Million USD | -133.489% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -382.256% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1185.787% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -296.695% |
| Acasti Pharma Inc. | 73.3 Million USD | -850.044% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -15197.43% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2566.408% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 27.821% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -13317.977% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -2956.854% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1249.499% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -285.399% |
| PepGen Inc. | 143.05 Million USD | -386.803% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1722.179% |
| United Therapeutics Corporation | 7.16 Billion USD | 90.283% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3529.825% |
| Solid Biosciences Inc. | 164.93 Million USD | -322.206% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -11758.839% |
| Immuneering Corporation | 102.58 Million USD | -578.837% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -16062.53% |
| Silo Pharma, Inc. | 7.74 Million USD | -8890.051% |
| Belite Bio, Inc | 94.64 Million USD | -635.807% |
| XOMA Corporation | 234.3 Million USD | -197.217% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -198.635% |
| Bionomics Limited | 27.64 Million USD | -2418.643% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -73.487% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -548.473% |
| uniQure N.V. | 831.68 Million USD | 16.269% |
| Cassava Sciences, Inc. | 151.66 Million USD | -359.164% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -15534.316% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -154.261% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1686.511% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -16997.042% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1790.75% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -9539.839% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -19723.0% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -5791.058% |
| Altimmune, Inc. | 210.64 Million USD | -230.603% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 10.477% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -548.473% |
| Compugen Ltd. | 121.33 Million USD | -473.938% |
| Peak Bio, Inc. | 2.59 Million USD | -26720.905% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -304.105% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1233.81% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -103.704% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1902.651% |
| Zura Bio Limited | 100.84 Million USD | -590.561% |
| PolyPid Ltd. | 15.37 Million USD | -4430.198% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -483.792% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1902.651% |
| Instil Bio, Inc. | 325.63 Million USD | -113.857% |
| argenx SE | 4.54 Billion USD | 84.669% |
| Immunome, Inc. | 148.54 Million USD | -368.818% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -343.909% |
| Verona Pharma plc | 308.12 Million USD | -126.007% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -700.816% |
| Shattuck Labs, Inc. | 159.56 Million USD | -336.428% |
| CervoMed Inc. | 9.97 Million USD | -6883.009% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -269.52% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -6015.051% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -288.162% |
| Moolec Science SA | 24.05 Million USD | -2795.404% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -11283.478% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -302.662% |
| AnaptysBio, Inc. | 452.38 Million USD | -53.934% |
| Design Therapeutics, Inc. | 289.64 Million USD | -140.428% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -856.24% |
| NeurAxis, Inc. | 509.49 Thousand USD | -136580.026% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -12753.119% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1613.623% |
| Achilles Therapeutics plc | 161.45 Million USD | -331.314% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -700.816% |
| 180 Life Sciences Corp. | 5.25 Million USD | -13140.521% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -888.789% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -8034.724% |
| Nutriband Inc. | 7.51 Million USD | -9163.905% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -173.428% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -249.412% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -813.743% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1102.4% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -32.256% |
| Palisade Bio, Inc. | 14.05 Million USD | -4855.75% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -231.145% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 52.293% |
| Neurogene Inc. | 222.57 Million USD | -212.878% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -7.696% |
| AEON Biopharma, Inc. | 6.84 Million USD | -10073.587% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -53.714% |
| Sesen Bio, Inc. | 189.17 Million USD | -268.117% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -156.148% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -4978.68% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 10.76% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -160.823% |
| Athira Pharma, Inc. | 160.24 Million USD | -334.573% |
| Vaccinex, Inc. | 3.63 Million USD | -19078.794% |
| HCW Biologics Inc. | 28.51 Million USD | -2342.275% |
| XOMA Corporation | 234.3 Million USD | -197.217% |
| Nektar Therapeutics | 398.03 Million USD | -74.956% |
| Arvinas, Inc. | 1.3 Billion USD | 46.621% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -3987.389% |
| Merus N.V. | 458.49 Million USD | -51.885% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -240.752% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -286.441% |
| Rezolute, Inc. | 132.73 Million USD | -424.633% |
| Clene Inc. | 52.34 Million USD | -1230.471% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -4566.227% |
| BeyondSpring Inc. | 24.8 Million USD | -2707.086% |
| Synlogic, Inc. | 75.55 Million USD | -821.75% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -5770.696% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -7336.801% |
| Peak Bio, Inc. | 2.59 Million USD | -26720.905% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -298.313% |
| Krystal Biotech, Inc. | 818.35 Million USD | 14.905% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -189.631% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 4.052% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -19367.378% |
| MannKind Corporation | 475.19 Million USD | -46.546% |
| Ikena Oncology, Inc. | 192.09 Million USD | -262.525% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -5106.984% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -497.553% |
| Gossamer Bio, Inc. | 311.91 Million USD | -123.259% |
| CohBar, Inc. | 16.36 Million USD | -4155.14% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1880.44% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -9419.918% |
| Legend Biotech Corporation | 1.84 Billion USD | 62.329% |
| Mural Oncology plc | 301.74 Million USD | -130.785% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2130.921% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -12159.372% |
| Disc Medicine, Inc. | 367.99 Million USD | -89.236% |
| Champions Oncology, Inc. | 26.13 Million USD | -2564.863% |
| REGENXBIO Inc. | 573.97 Million USD | -21.327% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -25614.924% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -351.066% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -5666.862% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -104.797% |
| Vaxart, Inc. | 91.83 Million USD | -658.338% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1062.499% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -369.491% |
| Cellectis S.A. | 334.27 Million USD | -108.329% |
| Longeveron Inc. | 12.17 Million USD | -5618.361% |
| Repare Therapeutics Inc. | 253.9 Million USD | -174.273% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 78.669% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -246.723% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 66.658% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -42754.277% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -150.758% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -326.972% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -401.919% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2628.556% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.936% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 39.651% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -5602.156% |
| Veru Inc. | 50.59 Million USD | -1276.36% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1428.729% |
| Cingulate Inc. | 3.49 Million USD | -19845.432% |
| Passage Bio, Inc. | 150.54 Million USD | -362.574% |
| Context Therapeutics Inc. | 16.06 Million USD | -4235.389% |
| Exicure, Inc. | 11.58 Million USD | -5913.661% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -85.184% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -330.817% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -3885.703% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -109.284% |
| Nuvalent, Inc. | 732.38 Million USD | 4.916% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -4559.919% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -677.611% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -4807.209% |
| OmniAb, Inc. | 401.98 Million USD | -73.236% |
| Anew Medical, Inc. | 19.45 Million USD | -3479.275% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2505.581% |
| Lipocine Inc. | 23 Million USD | -2927.607% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -398.102% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -127.9% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -729.606% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -472.965% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -8676.081% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 21.07% |
| Ocugen, Inc. | 64.54 Million USD | -978.876% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -459.159% |
| Q32 Bio Inc. | 306.11 Million USD | -127.487% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -16449.002% |
| Alumis Inc. Common Stock | 89.61 Million USD | -677.108% |
| Equillium, Inc. | 50.53 Million USD | -1278.156% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -826.101% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1587.237% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -40843.103% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2563.946% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -980.651% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -18584.22% |
| Dominari Holdings Inc. | 57.55 Million USD | -1109.879% |
| Edesa Biotech, Inc. | 8.89 Million USD | -7732.933% |
| vTv Therapeutics Inc. | 11.01 Million USD | -6220.403% |
| Bio-Techne Corporation | 2.81 Billion USD | 75.246% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 25.689% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 14.18% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -150.799% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1569.901% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -4.313% |
| Nkarta, Inc. | 378.88 Million USD | -83.798% |
| BioCardia, Inc. | 2.98 Million USD | -23213.76% |
| Iterum Therapeutics plc | 26.25 Million USD | -2551.975% |